Hase 2 studies. 3.4. Oxazolidinones utezolid (Formerly PNU-100480) (Pfizer) and AZD5847 (AstraZeneca). Sutezolid (formerly PNU100480, Pfizer) and AZD5847 (AstraZeneca) are new oxazolidinones in phase 2 development for TB [50]. Sutezolid is largely metabolized by flavin monooxygenases to sulfoxide and sulfone derivatives [51]. The sulfoxide metabolite is present in plasma at five to seven times the
Hase 2 studies. 3.4. Oxazolidinones utezolid (Formerly PNU-100480) (Pfizer) and AZD5847 (AstraZeneca). Sutezolid (formerly PNU100480, Pfizer) and AZD5847 (AstraZeneca) are new oxazolidinones in phase 2 development for TB [50]. Sutezolid is largely metabolized by flavin monooxygenases to sulfoxide and sulfone derivatives [51]. The sulfoxide metabolite is present in plasma at five to seven times the
Assisted with article writing. This project was funded with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract no. HHSN2722000900050C (`TB Clinical Diagnostics Research Consortium'), and under grant # K23AI089259.Int. J. Environ. Res. Public Health 2011, 8, 2524-2532; doi:10.3390